Instruction for use: Inosine pranobex

Trade name of the drug – Groprinosin, Inosine pranobex, Isoprinosine, Normomed

The Latin name of the substance Inosine pranobex

Inosinum pranobexum (genus. Inosini pranobexi)

Chemical name

The inosine compound with 1- (dimethylamino) -2-propanol-4- (acetylamino) benzoate (salt) in a ratio of 1: 3

Gross Formula

C₅₂H₇₈N₁₀O₁₇

Pharmacological groups:

Antiviral drugs (excluding HIV)

Interferon Inductors

The nosological classification (ICD-10)

A85 Other viral encephalitis, not elsewhere classified

B00 Infections caused by the herpes simplex virus [herpes simplex]: Herpes simplex; Herpes virus; Herpes simplex virus; Herpes simplex virus type I and II; HSV; Herpes; Herpes simplex / herpes simplex /; Herpes lips; Herpes simplex; Herpes in patients with immunodeficiency; Labial herpes; Acute herpetic disease of the mucous membranes; Herpes simplex; Herpes simplex skin and mucous membranes; Herpes simplex with skin and mucous membrane damage; Recurrent herpes; Urogenital herpetic infection; Chronic recurrent herpesvirus infection; Herpes-viral infections of various localizations

B00.4 Herpetic encephalitis (G05.1 *): Encephalitis caused by the herpes simplex virus

B01 Varicella [varicella]: Chicken pox; Newborn chickenpox; Varicella Zoster; Smallpox chickenpox; Herpes Varicella zoster

B02 Shingles [herpes zoster]: Herpes zoster; Herpes zoster; Shingles Herpes; Localized shingles; Infection caused by the herpes zoster virus; Shingles

B05 Measles: Koplik Spots; Koryvyaya rash on the mucous cheek

B07 Viral Warts: Warts; Human Wart Virus; Vulgar warts; Flat wart; Flat and vulgar wart in children; Plantar wart; Common wart; Common plantar wart; Skin Papillomas

B19 Viral hepatitis, unspecified: Anemia without hepatitis; Viral hepatitis; Viral hepatitis in children; Infection of the liver; Acute liver infection

B25 Cytomegalovirus: Generalized CMV infection in patients with AIDS; Cytomegalovirus infection in patients with impaired immunity; Cytomegalovirus infection; Cytomegalovirus infection in patients with habitual miscarriage Cytomegalovirus retinitis; Cytomegalovirus retinitis in AIDS patients; CMV; CMV in AIDS patients; CMV infection; CMV infection in the presence of immunodeficiency; CMV infection in cancer patients with immunosuppression; CMV-pneumonia; CMV retinitis in patients with weakened immunity; CMV retinitis in AIDS patients

B26 Epidemic parotitis: Parotitis; Infectious parotitis (mumps)

B34 Viral infection of unspecified site: Viral respiratory tract infections; Infections viral; Viral infection; Viral infections

D23 Other benign neoplasms of the skin: Benign neoplasm of skin; Condyloma; Papilloma; Dermatofibroma; Dysplastic nevi; Keratoacanthoma; Benign Skin Tumors; Exophytic papillomas

D84.9 Unspecified Immunodeficiency: Pneumonia in immunodeficient states; Autoimmune disease; Autoimmune diseases; Severe immunodeficiency; immune deficiency; Immunodeficiency; immunodeficiency diseases; Immunodeficiency states due to surgery; Immunotherapy for cancer; Immunomodulation; Infections in patients with weakened immune systems; Correction of immune deficiency; Correction of immunodeficiencies; Correction of a weakened immune system; Correction of a weakened immunity in immunodeficient states; Violation of immunity; Violation of the immune status; Immune System Disorders; Primary immunodeficiency; Maintaining immunity; Lowering the body's defenses; Lowering the immunity; Lowering the immunity of colds and infectious diseases; The decrease of the immune status; Lowered resistance to infections; Lowered resistance to infections and colds; Lowered resistance; Immunosuppression; Predisposition to colds; acquired immune deficiencies; Radiation immunodeficiency; The development of immunodeficiency; Immune dysfunction syndrome; immunodeficiency syndrome; primary immunodeficiency syndrome; Reducing the body's defenses; Immunosuppression; Reduced immune defense; Reducing local immunity; Reducing the total body resistance; The decrease in cell-mediated immunity; Reduced resistance to infections in children; Reducing the body's resistance; Reduced resistance; reduced immunity; Status immunodeficiency; Stimulation of the processes of nonspecific immunity; Heavy selective secondary immunodeficiency; immunity Oppression; Primary immunodeficiency

G04 Encephalitis, myelitis and encephalomyelitis: Disseminated acute encephalomyelitis; Leukoencephalitis; Meningomielitis; Myelitis; Acute encephalitis; Acute encephalomyelitis; Chronic encephalitis; Chronic encephalomyelitis; Encephalitis; Encephalomyelitis; Inflammation of meninges

J20 Acute bronchitis: Acute bronchitis; Acute bronchial disease; Disease of the bronchi; Viral bronchitis; Infectious bronchitis

Z51.0 Radiotherapy course: Supplement to external radiation therapy; Local X-Ray Irradiation; Radiation therapy; Brain edema associated with radiation therapy; Lesion in radiation therapy; Radiotherapy

Z54 recovery period: The recovery period; The recovery period after illness; Recovery; The recovery from the flu and colds; Recovery after illness; The lack of mineral salts in the period of convalescence; The period of recovery after illness; The period of recovery after illness and surgery; The period of recovery after a serious illness; The period of convalescence after illness; rehabilitation period; rekovalestsentsii period after infectious diseases; decubation; The period of convalescence after surgery and infectious diseases; The period of convalescence after prolonged infections; The period of convalescence after serious diseases; The period of convalescence after severe infections; Rehabilitation period; convalescent state; Convalescence after illness; Convalescence after infectious diseases; Convalescence after debilitating diseases; Convalescence after infectious diseases; Convalescence at an elevated blood loss; Status of convalescence after illness

CAS code

36703-88-5

Pharmacology

Pharmacological action - antiviral, immunostimulating.

Increases the total number of T-lymphocytes and the production of interleukin-2, normal killer cells and T-helpers, improves the helper / suppressor ratio; Stimulates the chemotactic and phagocytic activity of monocytes, macrophages (synthesis of interleukin-1 in them), and polymorphonuclear cells; Enhances the synthesis of RNA and ribosomal protein. Simultaneously, it suppresses the replication of DNA and RNA viruses by binding to the ribosomes of the cell and changing their stereochemical structure.

After oral administration at a dose of 1500 mg Cmax inosine is achieved after 1 hour and is 600 μg / ml. Inosine is metabolized with the formation of uric acid. T1 / 2 inosine - 50 min, T1 / 2 1- (dimethylamino) -2-propanol-4- (acetylamino) benzoate (the second component of the complex) - 3-5 hours. It is excreted by the kidneys in the form of metabolites.

Application of the substance Inosine pranobex

Viral infections in patients with normal and weakened immune system, incl. Diseases caused by Herpes simplex virus types 1 and 2, Varicella zoster (including varicella), measles, mumps, cytomegalovirus, Epstein-Barr virus; Viral bronchitis; Acute and chronic viral hepatitis B and C; Diseases caused by the human papillomavirus; Subacute sclerosing panencephalitis; Chronic infectious diseases of the urinary and respiratory systems; Prevention of infections in stressful situations; The period of convalescence in postoperative patients and people undergoing severe illness; Immunodeficiency states; Radiotherapy.

Contraindications

Hypersensitivity, hyperuricemia, renal failure, nephro- and urolithiasis, propensity to extrasystole, autoimmune diseases, pregnancy, breast-feeding.

Application in pregnancy and breastfeeding

Contraindicated in pregnancy. At the time of treatment should stop breastfeeding.

Side effects of Inosine pranobex

From the nervous system and sensory organs: dizziness, a feeling of overwork, a headache.

On the part of the digestive system: at the beginning of treatment, dyspeptic phenomena (nausea, vomiting, diarrhea).

Other: transient increase in uric acid in the blood and urine, allergic reactions, in some cases - increased levels of hepatic transaminases, arthralgia.

Interaction

Immunosuppressants reduce effectiveness (simultaneous use should be avoided).

Routes of administration

Inside.

Precautions for the substance Inosine pranobex

Periodic determination of uric acid in the blood and urine is necessary. With prolonged use, continuous monitoring of liver function, kidney function, and peripheral blood pattern is required.